Hereditary Oncology Testing
Test in Focus
In this "Test in Focus" episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology test offerings, which use next-generation sequencing to detect germline alterations associated with increased risk for various cancers. Our comprehensive panels, disease-specific panels, and single gene assays leverage the clinical expertise of Mayo Clinic physicians, enabling individualized insights on a patient’s risk of developing secondary cancers or a hereditary cancer syndrome.
“We know inherited genetic alterations contribute to about 10% to 20% of cancers overall,” Dr. Shen says. “However, more studies are showing that universal genetic testing actually detects more patients with hereditary cancer syndromes than a guideline-based approach.”
Test results can indicate the likelihood of a clinical diagnosis of a hereditary cancer syndrome, advance understanding of a patient’s risk of developing additional cancers, assist in management and treatment decisions, and rule out hereditary causes, Dr. Shen says. The biggest benefit of using Mayo Clinic testing, however, is access to expert-backed testing across the oncological spectrum.
“Cancers can result from both somatic and germline mutations,” Dr. Shen says. “This series of new genetic panels completes our comprehensive cancer testing menu and allows us to offer a one-stop shop genetic service to physicians and cancer patients.”
Listen to learn more.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
COMCP | Hereditary Common Cancer Panel
Michelle Kluge, M.S., CGC, explains how Mayo Clinic Laboratories’ CYPZ assay provides accurate testing for congenital adrenal hyperplasia. Using an in-depth methodology that incorporates Sanger sequencing, MCL can provide clear answers for carriers and individuals clinically affected by the most common form of CAH.
Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.
Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' PCR assay that identifies two recently described staphylococcus species. The assay is unique in its ability to distinguish the new organisms from Staphylococcus aureus, providing clearer results that ultimately improve patient care.